


GLP-1 Receptor Agonist Market Sales to Top US\$ 19,253.8 Mn in Revenues by 2030 at a CAGR of 6.1% | Sanofi, Pfizer, Amgen

Glucagon-like peptide-1 (GLP-1) receptor agonists bind to GLP-1 receptors and activate it to stimulate physiological processes in the body.

BURLINGAME, CALIFORNIA, UNITED STATES, April 24, 2023 /EINPresswire.com/ -- Comprehensive analysis of the fastest-growing [GLP-1 Receptor Agonist Market](#) provides insights that will help stakeholders identify both opportunities and challenges. The 2023 market could see another significant year for GLP-1 Receptor Agonist. This report provides insights into the market structure, key players, and growth drivers. (company profiles are needed if you are looking to raise capital or win investors), Mergers and Acquisitions, and the market outlook. This report focuses on the GLP-1 Receptor Agonist Market during the 2030 evaluation period. This report also includes a GLP-1 Receptor Agonist Market growth analysis that incorporates Porter's five-factor analysis as well as supply chain analysis.



Glp 1 Receptor Agonist Market Analysis

The global GLP-1 receptor agonist market is estimated to be valued at US\$ 12,720.6 million in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period (2023-2030).

GLP-1 receptor agonists interact with GLP-1 receptors present in the pancreatic beta cells to stimulate insulin secretion. Thus, GLP-1 receptor agonists can be used for the treatment of diabetes. The benefits of using GLP-1 receptor agonist for the treatment of type-2 diabetes include inhibition of glucagon production from pancreatic alpha cells in case of high blood sugar levels. Glucagon is a hormone responsible for increasing the concentration of glucose in the blood by stimulating the liver to convert glycogen into glucose. Moreover, GLP-1 receptor agonists can promote proliferation of pancreatic beta-cell and decrease its apoptosis or cell

death.

The industry's behaviour is discussed in detail. It also outlines the future direction of the market that will ensure strong profits over the coming years. This report will provide a practical overview of the global market and its changing environment to help readers make informed decisions about market projects. This report will focus on the market that will allow the market to expand its operations in existing markets.

Get Sample with Latest Trends and Future Advancements at:

<https://www.coherentmarketinsights.com/insight/request-sample/4632>

This report helps both the market players and the market analysts to analyse the market in-depth. This will help the leading players decide on their business strategy and set goals. This report provides critical market information, including GLP-1 Receptor Agonist Market size, growth rates, and forecasts in key regions and countries, as well as growth opportunities in niche markets.

The GLP-1 Receptor Agonist report contains data based on demanding market research methods. This report provides all-around information that aids in the estimation of every part of the GLP-1 Receptor Agonist Market. This report was created by considering several aspects of market research and analysis. These include market size estimates, market dynamics, and company and market best practices. Entry-level marketing strategies, positioning, segmentation, competitive landscaping, and economic forecasting. Industry-specific technology solutions, roadmap analysis, targeting key buying criteria, and in-depth benchmarking of vendor offerings.

Key Market Segments

Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.

Detailed Segmentation:

Global GLP-1 Receptor Agonist Market, By Drug Class:

Exenatide

Liraglutide

Dulaglutide

Lixisenatide

Albiglutide

Semaglutide

Global GLP-1 Receptor Agonist Market, By Route of Administration:

Parenteral

Oral

Global GLP-1 Receptor Agonist Market, By Application:

Type 2 Diabetes Mellitus

Obesity

Liver Cirrhosis

Non-alcoholic Steatohepatitis

Others (Others include Cardiovascular Disease and Type-1 Diabetes)

Global GLP-1 Receptor Agonist Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global GLP-1 Receptor Agonist Market, By Region:

□ North America (U.S., Canada, Mexico)

□ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

□ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

□ Latin America (Colombia, Brazil, Argentina, Rest of Latin America)

□ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Direct Purchase this report now: <https://www.coherentmarketinsights.com/insight/buy-now/4632>

The report provides insights on the following pointers:

□ Market Penetration: Comprehensive information on the product portfolios of the top players in the GLP-1 Receptor Agonist market.

□ Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the market.

□ Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

□ Market Development: Comprehensive information about emerging markets. This report

analyses the market for various segments across geographies.

□ **Market Diversification:** Exhaustive information about new products, untapped geographies, recent developments, and investments in the GLP-1 Receptor Agonist market.

□□□□□□□□□□ □□□□□ □□□□□□□□□□

□ How is the GLP-1 Receptor Agonist Market along with regions like **North America**, **Europe**, **Asia-Pacific**, **Latin America**, **Middle East** and **Africa** are growing?

□ What Cutting-edge technologies is responsible for driving market growth?

□ What are the major applications of the GLP-1 Receptor Agonist market? What growth prospects are there for the market applications?

□ What stage are the key products in the GLP-1 Receptor Agonist Market?

□ What are the challenges that the (North America and Europe and Asia-Pacific and South America) must overcome to be commercially viable? Are their growth and commercialization dependent on cost declines or technological/application breakthroughs?

□ What are the prospects for the GLP-1 Receptor Agonist Market?

□ What is the difference between the performance characteristics of GLP-1 Receptor Agonist and established entities?

[illegible]

- GLP-1 Receptor Agonist Market provides an analysis of the changing competitive environment
- Analytical data and strategic planning methods are involved to help businesses make informed decisions.

■ Few **new entrants** for GLP-1 Receptor Agonist Market.

- It allows you to understand the key product segments.

Our team shed light on market dynamics such as **market volatility**, **market trends**, and **market segmentation**.

- It provides a regional analysis of the GLP-1 Receptor Agonist Market as well as business profiles for several stakeholders.

- It provides massive data on trending factors that can influence the development of the GLP-1 Receptor Agonist Market.

□ Get our Customized Research Report:

<https://www.coherentmarketinsights.com/insight/request-customization/4632>

□□□□ □□ □□□□□□□□:

- Chapter 1: Overview of GLP-1 Receptor Agonist market
- Chapter 2: Market status and forecast by regions
- Chapter 3: Market status and forecast by types
- Chapter 4: Market status and forecast by downstream industry
- Chapter 5: Market driving factor analysis
- Chapter 6: Market competition status by major manufacturers
- Chapter 7: Major manufacturer's overview and market data
- Chapter 8: Upstream and downstream market analysis
- Chapter 9: Cost and Gross Margin Analysis
- Chapter 10: Market status analysis
- Chapter 11: Conclusion
- Chapter 12: Research Findings and Reference

Other Trending Reports:

Diphtheria Vaccine Market -<https://www.globenewswire.com/news-release/2023/02/15/2608815/0/en/Global-Diphtheria-Vaccine-Market-to-Surpass-US-8-037-1-Million-by-2030-Says-Coherent-Market-Insights-CMI.html>

Tamiflu Oseltamivir Phosphate Market -<https://www.globenewswire.com/news-release/2023/02/20/2611467/0/en/Tamiflu-Oseltamivir-Phosphate-Market-to-Surpass-US-978-6-Million-by-2030-Says-Coherent-Market-Insights-CMI.html>

Digestive Drugs Market -<https://www.globenewswire.com/news-release/2023/02/22/2613260/0/en/Digestive-Drugs-Market-to-surpass-US-82-969-4-Million-by-2030-Says-Coherent-Market-Insights-CMI.html>

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical

business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Mr. Shah

Coherent Market Insights Pvt. Ltd.

+1 206-701-6702

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/629680605>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.